RTI Surgical Inc (NASDAQ:RTIX) has been upgraded to Hold in a report by Zacks Investment Research today.
- Updated: October 2, 2016
Zacks Investment Research has upgraded RTI Surgical Inc (NASDAQ:RTIX) to Hold in a statement released on Wednesday September 28, 2016.
Having a price of $3.06, RTI Surgical Inc (NASDAQ:RTIX) traded 2.29% higher on the day. With the last stock price down -14.06% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. RTIX has recorded a 50-day average of $3.20 and a two hundred day average of $3.64. Trade Volume was down over the average, with 127,427 shares of RTIX changing hands under the typical 140,136
Recent Performance Chart
RTI Surgical Inc has PE ratio of 44.08 with a one year low of $2.81 and a one year high of $5.74 and has a market capitalization of $0.
General Company Details For RTI Surgical Inc (NASDAQ:RTIX)
RTI Surgical, Inc. is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company's business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties. It processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes, and manufactures metal and synthetic implants for distribution to hospitals and surgeons. The Company distributes its implants and services in approximately 50 states and in over 45 countries across the world.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.